{
  "title": "Teens with obesity lose 15% of body weight in trial of repurposed diabetes drug",
  "link": "https://arstechnica.com/?p=1895135",
  "dc:creator": "Beth Mole",
  "pubDate": "Thu, 03 Nov 2022 22:42:42 +0000",
  "category": [
    "Science",
    "Biology",
    "BMI",
    "CDC",
    "fda",
    "medicine",
    "obesity",
    "overweight",
    "semaglutide",
    "Teens",
    "wegovy"
  ],
  "guid": "https://arstechnica.com/?p=1895135",
  "description": "The drug could be a useful new tool for treating childhood obesity.",
  "content:encoded": "<div id=\"rss-wrap\">\n<figure class=\"intro-image intro-left\">\n  <img src=\"https://cdn.arstechnica.net/wp-content/uploads/2019/12/GettyImages-629405043-800x533.jpg\" alt=\"Woman on a kg weight scale \">\n      <p class=\"caption\" style=\"font-size:0.8em\"><a href=\"https://cdn.arstechnica.net/wp-content/uploads/2019/12/GettyImages-629405043.jpg\" class=\"enlarge-link\" data-height=\"3113\" data-width=\"4671\">Enlarge</a> <span class=\"sep\">/</span> Woman on a kg weight scale  (credit: <a rel=\"nofollow\" class=\"caption-link\" href=\"https://www.gettyimages.com/detail/news-photo/woman-on-weight-scale-news-photo/629405043?adppopup=true\">Getty | BSIP</a>)</p>  </figure>\n\n\n\n\n\n\n<div><a name=\"page-1\"></a></div>\n<p>A repurposed Type 2 diabetes drug helped teens with obesity lose a significant amount of body weight, lowered their risk factors for cardiovascular disease, and improved their weight-related quality of life over a 68-week clinical trial, researchers <a href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa2208601?query=featured_home\">reported</a> this week in the New England Journal of Medicine.</p>\n<p>The drug is semaglutide (brand name Wegovy), which was first approved to treat Type 2 diabetes in 2017 but has since also <a href=\"https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014\">proven useful for weight loss in adults who are obese or overweight</a>. The drug works by mimicking a hormone called glucagon-like peptide-1 (GLP-1) that targets areas of the brain that regulate appetite and food intake, the Food and Drug Administration explained while approving its use for weight loss in adults.</p>\n<p>The new data suggests that it may also substantially help teens struggling with obesity and overweight issues improve their health and outlook as they head into adulthood. <a href=\"https://www.cdc.gov/obesity/data/childhood.html\">One in five children and teens</a> in the US has obesity, which can set children up for serious health conditions, including high blood pressure, high cholesterol, Type 2 diabetes, breathing problems, and joint problems, according to the Centers for Disease Control and Prevention.</p></div><p><a href=\"https://arstechnica.com/?p=1895135#p3\">Read 6 remaining paragraphs</a> | <a href=\"https://arstechnica.com/?p=1895135&comments=1\">Comments</a></p>"
}